Lysosomal acid glucosylceramidase · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Lysosomal acid glucosylceramidase shows clinical signal disease relevance led by Gaucher disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P04062. Start with Gaucher disease, then reuse UniProt P04062 as the stable protein anchor across project notes and exports.
Start with Gaucher disease, then reuse UniProt P04062 as the stable protein anchor across project notes and exports.
Lysosomal acid glucosylceramidase shows clinical signal disease relevance led by Gaucher disease. 1 linked drug remains visible in the same block.
Start review with Gaucher disease because it currently carries clinical signal support. Linked drugs include AFEGOSTAT TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyLysosomal acid glucosylceramidase
Review this target as Lysosomal acid glucosylceramidase, mapped to UniProt P04062. Sequence length is 536 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Lysosomal acid glucosylceramidase as ChEMBL target CHEMBL2179, mapped to UniProt P04062. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Lysosomal acid glucosylceramidase is the right protein anchor across sources, using UniProt P04062 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Gaucher disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Lysosomal acid glucosylceramidase |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P04062 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Lysosomal acid glucosylceramidase |
| UniProt Accession | P04062 |
| Component Type | Protein |
| Sequence Length | 536 aa |
Lysosomal acid glucosylceramidase
Review this target as Lysosomal acid glucosylceramidase, mapped to UniProt P04062. Sequence length is 536 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Lysosomal acid glucosylceramidase shows clinical signal disease relevance led by Gaucher disease.
Start review with Gaucher disease because it currently carries clinical signal support. Linked drugs include AFEGOSTAT TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL2029773 | 9.4 | Ki | 0.4 | Preclinical |
| CHEMBL5192083 | 9.22 | IC50 | 0.6 | Preclinical |
| CHEMBL3684925 | 9.05 | Ki | 0.9 | Preclinical |
| CHEMBL3692692 | 9.02 | Ki | 0.95 | Preclinical |
| CHEMBL2164231 | 9.0 | Ki | 1.0 | Preclinical |
| CHEMBL3289676 | 9.0 | Ki | 1.0 | Preclinical |
| CHEMBL4080589 | 9.0 | Ki | 1.0 | Preclinical |
| CHEMBL3350092 | 8.92 | Ki | 1.2 | Preclinical |
| CHEMBL3692694 | 8.81 | Ki | 1.56 | Preclinical |
| CHEMBL206468 | 8.77 | Ki | 1.7 | Clinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 234 | 603 | 6.2 |
| cell-based format | 70 | 86 | 6.3 |
| assay format | 56 | 41 | 5.0 |
| tissue-based format | 13 | 25 | 5.7 |
| organism-based format | 1 | 4 | 7.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 28 | 0 | — |
| tissue-based format | 4 | 0 | — |
| cell-based format | 1 | 4 | 5.4 |